Successful Palliation with Octreotide of a Neuroendocrine Syndrome from Malignant Melanoma

Journal of Pain and Symptom Management

Volumn 32, Issue 2, 2006, Pages 191-195

  Jahng, Alexander W ^a   Liao, Solomon S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

chromogranin; Melanoma; neuroendocrine syndrome; octreotide; somatostatin

Indexed keywords

CHROMOGRANIN A; CISPLATIN; OCTREOTIDE; ONDANSETRON;

ABDOMINAL PAIN; ADULT; ARTICLE; BLOOD CHEMISTRY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; DEGRANULATION; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FEVER; HORMONE RELEASE; HOT FLUSH; HUMAN; HYPERHIDROSIS; HYPOTENSION; LIVER METASTASIS; MELANOMA; NAUSEA; NEUROENDOCRINE DISEASE; SYMPTOMATOLOGY; TREATMENT OUTCOME; VAGINA MELANOMA; VAGINA TUMOR; VOMITING;

ABDOMINAL PAIN; CHEST PAIN; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; LIVER NEOPLASMS; MELANOMA; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; PALLIATIVE CARE; SYNDROME; TREATMENT OUTCOME; VAGINAL NEOPLASMS;

EID: 33746273995     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2006.02.014     Document Type: Article

References (33)

1. Barakat M.T., Meeran K., and Bloom S.R. Neuroendocrine tumours. Endocr Relat Cancer 11 1 (2004) 1-18
2. Ramage J.K., Davies A.H., Ardill J., et al., on behalf of UKNETwork for Neuroendocrine Tumours. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 54 Suppl 4 (2005) iv1-iv16
3. Oberg K., Kvols L., Caplin M., et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15 6 (2004) 966-973
4. Mosdell K.W., and Visconti J.A. Emerging indications for octreotide therapy, Part 1. Am J Hosp Pharm 51 9 (1994) 1184-1192
5. Fried M. Octreotide in the treatment of refractory diarrhea. Digestion 60 Suppl 2 (1999) 42-46
6. Cairns W., and Malone R. Octreotide as an agent for the relief of malignant ascites in palliative care patients. Palliat Med 13 5 (1999) 429-430
7. Mercadante S. The role of octreotide in palliative care. J Pain Symptom Manage 9 6 (1994) 406-411
8. Pistevou-Gombaki K., Eleftheriadis N., Plataniotis G.A., Sofroniadis I., and Kouloulias V.E. Octreotide for palliative treatment of hepatic metastases from non-neuroendocrine primary tumours: evaluation of quality of life using the EORTC QLQ-C30 questionnaire. Palliat Med 17 3 (2003) 257-262
9. Erstad B.L. Octreotide for acute variceal bleeding. Ann Pharmacother 35 5 (2001) 618-626
10. Li-Ling J., and Irving M. Somatostatin and octreotide in the prevention of postoperative pancreatic complications and the treatment of enterocutaneous pancreatic fistulas: a systematic review of randomized controlled trials. Br J Surg 88 2 (2001) 190-199
11. Matsumoto J., Kimura W., Kawauchi M., et al. Management of severe acute pancreatitis with a somatostatin analog in a patient undergoing surgery for dissecting thoracic aneurysm: report of a case. Surg Today 29 9 (1999) 911-914
12. Comaru-Schally A.M., and Schally A.V. A clinical overview of carcinoid tumors: perspectives for improvement in treatment using peptide analogs (review). Int J Oncol 26 2 (2005) 301-309
13. Cramer S.F. The origin of epidermal melanocytes. Implications for the histogenesis of nevi and melanomas. Arch Pathol Lab Med 115 2 (1991) 115-119
14. Horai T., Nishihara H., Hattori S., and Tateishi R. Malignant melanoma producing serotonin. Cancer 43 1 (1979) 294-298
15. Slominski A., Semak I., Pisarchik A., et al. Conversion of L-tryptophan to serotonin and melatonin in human melanoma cells. FEBS Lett 511 1-3 (2002) 102-106
16. Darvas Z., Sakurai E., Schwelberger H.G., et al. Autonomous histamine metabolism in human melanoma cells. Melanoma Res 13 3 (2003) 239-246
17. Falus A., Hegyesi H., Lazar-Molnar E., et al. Paracrine and autocrine interactions in melanoma: histamine is a relevant player in local regulation. Trends Immunol 22 12 (2001) 648-652
18. Nagahama M., Funasaka Y., Fernandez-Frez M.L., et al. Immunoreactivity of alpha-melanocyte-stimulating hormone, adrenocorticotrophic hormone and beta-endorphin in cutaneous malignant melanoma and benign melanocytic naevi. Br J Dermatol 138 6 (1998) 981-985
19. Khare V.K., Albino A.P., and Reed J.A. The neuropeptide/mast cell secretagogue substance P is expressed in cutaneous melanocytic lesions. J Cutan Pathol 25 1 (1998) 2-10
20. Ellerhorst J.A., Naderi A.A., Johnson M.K., et al. Expression of thyrotropin-releasing hormone by human melanoma and nevi. Clin Cancer Res 10 (2004) 5531-5536
21. Banerjee S.S., Menasce L.P., Eyden B.P., and Brain A.N. Malignant melanoma showing ganglioneuroblastic differentiation: report of a unique case. Am J Surg Pathol 23 5 (1999) 582-588
22. Lo Scocco G., Di Lernia V., and Bisighini G. Syndrome of inappropriate secretion of antidiuretic hormone in a patient affected by metastatic melanoma. Melanoma Res 8 4 (1998) 367-369
23. Kefford R.F., and Milton G.W. Fatal inappropriate ADH secretion in melanoma. Med J Aust 144 6 (1986) 333-334
24. Sanghera P., and El-Modir A. Malignant melanoma and SIADH. Clin Oncol (R Coll Radiol) 17 3 (2005) 199-200
25. Koopmans K.P., Brouwers A.H., De Hooge M.N., et al. Carcinoid crisis after injection of 6-18F-fluorodihydroxyphenylalanine in a patient with metastatic carcinoid. J Nucl Med 46 7 (2005) 1240-1243
26. Kharrat H.A., and Taubin H. Carcinoid crisis induced by external manipulation of liver metastasis. J Clin Gastroenterol 36 1 (2003) 87-88
27. Vaughan D.J., and Brunner M.D. Anesthesia for patients with carcinoid syndrome. Int Anesthesiol Clin 35 4 (1997) 129-142
28. Tony J.C. The chromogranin-secretogranin family. [Letter]. N Engl J Med 348 25 (2003) 2579-2580
29. Eyden B., Pandit D., and Banerjee S.S. Malignant melanoma with neuroendocrine differentiation: clinical, histological immunohistochemical and ultrastructural features of three cases. Histopathology 47 4 (2005) 402-409
30. Lum S.S., Fletcher W.S., O'Dorisio M.S., et al. Distribution and functional significance of somatostatin receptors in malignant melanoma. World J Surg 25 4 (2001) 407-412
31. Ardjomand N., Ardjomand N., Schaffler G., Radner H., and El-Shabrawi Y. Expression of somatostatin receptors in uveal melanomas. Invest Ophthalmol Vis Sci 44 3 (2003) 980-987
32. Meyers F.J., Linder J., Beckett L., et al. Simultaneous care: a model approach to the perceived conflict between investigational therapy and palliative care. J Pain Symptom Manage 28 6 (2004) 548-556
33. Lorenz K.A., Asch S.M., Rosenfeld K.E., Liu H., and Ettner S.L. Hospice admission practices: where does hospice fit in the continuum of care?. J Am Geriatr Soc 52 5 (2004) 725-730